On October 23rd, 2014, we updated our
By continuing to use LinkedIn’s SlideShare service, you agree to the revised terms, so please take a few minutes to review them.
Senology.org Newsletter - March 2, 2012Document Transcript
Senology Newsletter Page 1 of 3 Senology.org - Newsletter International Senologic and Oncologic Scientific Community (ISOSC) "Connecting specialists worldwide" Editor-in-Chief: Gian Paolo Andreoletti, MD Subscribe Unsubscribe Contact Back Issues Connecting Specialists Worldwide Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates Literature Selection McCarty CA et al.: "Alcohol, genetics and risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial", Breast Cancer Res Treat. 2012 Feb 14. [Epub ahead of print] Robertson L et al.: "BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years", Br J Cancer. 2012 Feb 14 [Epub ahead of print] Malmgren JA et al.: "Impact of mammography detection on the course of breast cancer in women aged 40-49 years", Radiology. 2012 Mar;262(3):797-806 Ying X et al.: "A Comparison of Mammography and Ultrasound in Women with Breast Disease: A Receiver Operating Characteristic Analysis", Breast J. 2012 Feb 23 [Epub ahead of print] Bidard FC et al.: "Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer : a prospective observational study", Breast Cancer Res. 2012 Feb 13;14(1):R29. [Epub ahead of print] Peron J et al.: "First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer", Bull Cancer. 2012 Feb 1;99(2):18-25 Johnston SJ et al.: "A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up", Ann Oncol. 2012 Feb 21. [Epub ahead of print] de Blacam C et al.: "High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national surgical quality improvement program database", Ann Surg. 2012 Mar;255(3):551-5 Hamamoto Y et al.: "Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer", Breast Cancer. 2012 Feb 15. [Epub ahead of print] Eldeeb H et al.: "Hypofractionation in post-mastectomy breast cancer patients: seven-year follow-up", Med Oncol. 2012 Feb 22. [Epub ahead of print] Mann E et al.: "Cognitive behavioural treatment for women who have menopausal symptoms afterhttp://www.senology.org/newsletter/Newsl_Mar2012.htm 02/03/2012
Senology Newsletter Page 2 of 3 breast cancer treatment (MENOS 1): a randomised controlled trial", Lancet Oncol. 2012 Feb 14. [Epub ahead of print] Comment "A new procedure for noninvasive detection of breast cancer lymph node metastasis", Narges Tafreshi - Department of Molecular and Functional Imaging, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA ""Using two cell surface markers found to be highly expressed in breast cancer lymph node metastases, our team, which included colleagues at University of Florida and Arizona, developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastases. The new procedure could spare breast cancer patients invasive and unreliable sentinel lymph node biopsies and surgery-associated negative side effects." (Comment on: Tafreshi NK et al.: "Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes", Clin Cancer Res. 2012 Jan 1;18 (1):207-19) Discussion - "BRCA1 testing should be offered to women with triple-negative breast cancer diagnosed below 50 years" - Share your opinion on LinkedIn® Calendar of Events 3rd Asian Breast Cancer Congress, March 3-4, 2012, Bangalore, India 29th Annual Miami Breast Cancer Conference, March 14-17, 2012, Miami, FL, USA 8th European Breast Cancer Conference, March 21-24, 2012, Vienna, Austria 4th IMPAKT Breast Cancer Conference, May 3-5, 2012, Brussels, Belgium 17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13, 2012, Salvador, Bahia, Brazil Fragments of History William S Halsted (New York, 1852-1922), "The results of radical operations for the cure of carcinoma of the breast", Ann Surg. July 1907:46(1):1-19: “The Operation - We must remove not only a very large amount of skin and a much larger area of subcutaneous fat and fascia, but also strip the sheaths from the upper part of the rectus, the serratus magnus, the subscapularis, and at times from parts of the latissimus dorsi and the teres major. Both pectoral muscles are, of course, removed" Literature Selection Amant F et al.: "Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study", Lancet Oncol. 2012 Feb 9. [Epub ahead of print] Beukelman T et al.: "Rates of malignancy associated with juvenile idiopathic arthritis and its treatment", Arthritis Rheum. 2012 Feb 10. doi: 10.1002/art.34348. [Epub ahead of print] Zauber AG et al.: "Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths", N Engl J Med. 2012 Feb 23;366(8):687-96 Wisnivesky JP et al.: "Postoperative radiotherapy for elderly patients with stage III lung cancer", Cancer. 2012 Feb 13. doi: 10.1002/cncr.26585. [Epub ahead of print] Loeb S et al.: "Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer", BJU Int. 2012 Feb 1.[Epub ahead of print] Tewari A et al.: "Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy", BJU Int. 2012 Feb;109(4):596-602 Bala I et al.: "Efficacy of Gabapentin for Prevention of Postoperative Catheter-related Bladder Discomfort in Patients Undergoing Transurethral Resection of Bladder Tumor", Urology. 2012 Feb 4. [Epub ahead of print] Tuveson DA et al.: "nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer", Cancer Discov 2012 Feb 28 [Epub ahead of print] Healthcare Companies Newshttp://www.senology.org/newsletter/Newsl_Mar2012.htm 02/03/2012
Senology Newsletter Page 3 of 3 Oncotype DX Newsletter - Genomic Health Literature Selection Mirick DS et al.: "Night Shift Work and Hormone Levels in Women", Cancer Epidemiol Biomarkers Prev. 2012 Feb 7. [Epub ahead of print] Burbos N et al.: "Postmenopausal vaginal bleeding in women using hormone replacement therapy", Menopause Int. 2012 Feb 9. [Epub ahead of print] Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation. TalkAboutHealth Q&A of the month "What genetic mutations of non-small cell lung cancer (NSCLC) currently have treatment options?" "Genetic mutations play a key role in NSCLC. Identifying certain, key mutations can help select targeted therapy. The two most important mutations in lung cancer right now are the EGFR and EML- 4ALK mutation and are found in the subtype of lung cancer called adenocarcinoma. These mutations are more commonly found in female, asian, non-smokers. However, they are also found in smokers and males, but to a lesser degree. Patients with the EGFR mutation are generally treated with Tarceva as first line treatment, rather than chemotherapy. Similarly, patients with the EML-4 ALK mutation are treated with a recently approved drug called Xalqori (Crizotinib). Generally patients with these mutations who are treated with the appropriate drug do very well when compared to patients who dont have the mutation and are treated with chemotherapy. It is important to note, that while other mutations in lung cancer do exist and can be identified (KRAS mutation, PIK-3 mutation, MET to name a few), there are no approved drugs that target these mutations like Tarceva and Xalqori do for EGFR and EML-4ALK and thus patients with these mutations are treated with standard chemotherpay. That said, there are several clinical trials open looking a new drugs that target these mutations" (Answer by Benjamin Levy, Assistant Professor of Medicine at Albert Einstein College of Medicine and an attending physician at Continuum Cancer Centers of New York) Unsubscribe www.senology.orghttp://www.senology.org/newsletter/Newsl_Mar2012.htm 02/03/2012